Glukagonoma: Olgu sunumu

Amaç & Hipotez:Glukagonoma sendromu, nekrotik migratuar eritem, diabetes mellitus, kilo kaybı, anemi, stomatit, tromboembolizm, gastrointestinal- nöropsikiyatrik bozukluklarla karekterize, pankreasın alfa hücrelerinden kaynaklanan paraneoplastik bir fenomendir.

📊

Temel Bulgular & Veri:Glukagonoma sendromu, nekrotik migratuar eritem, diabetes mellitus, kilo kaybı, anemi, stomatit, tromboembolizm, gastrointestinal- nöropsikiyatrik bozukluklarla karekterize, pankreasın alfa hücrelerinden kaynaklanan paraneoplastik bir fenomendir.

💡

Sonuç & Katkı:Bu yazıda glukagonomalı bir olgu sunulurken sendromla ilgili literatür de gözden geçirilmiştir.

🔬Tür:Literatür & Derleme Çalışması

📍Kapsam:Genişletilmiş Akademik Örneklem

⚙️Değişkenler:Orta Yaş · Diabetes mellitus · Tanı

Özet

Glukagonoma sendromu, nekrotik migratuar eritem, diabetes mellitus, kilo kaybı, anemi, stomatit, tromboembolizm, gastrointestinal- nöropsikiyatrik bozukluklarla karekterize, pankreasın alfa hücrelerinden kaynaklanan paraneoplastik bir fenomendir. Bu yazıda glukagonomalı bir olgu sunulurken sendromla ilgili literatür de gözden geçirilmiştir.

Abstract

Glucagonoma syndrome is a paraneoplastic phenomenon characterized by alpha cell pancreatic tumor; necrolytic migratory erythema, diabetes, weight loss, anemia, stomatitis, thromboembolism and gastrointestinal-neuropsychiatric disturbances. We presented a case of glucagonoma and rewieved the literature on this syndrome.

Anahtar kelimeler

Orta Yaş Diabetes mellitus Tanı ayırıcı Glukagonom Cerrahi işlemler operatif Tedavi sonucu Karsinom adacık hücreli Middle Age Diabetes Mellitus Diagnosis Differential Glucagonoma Surgical Procedures Operative Treatment Outcome Carcinoma Islet Cell

🔖

Bu Makaleye Atıf Yap

ALARSLAN, P., YILDIRIM, A., ÖZKAN, D., SALMAN, T., AYKAS, A., BAŞKAN, Z., SOP, G. (2002). Glukagonoma: Olgu sunumu. Ege Tıp Dergisi, Cilt: 41 - Sayı: 4, 247–249. https://ajindex.com/articles/223056

📄 Tam Metin PDF Okuyucu

Yeni Sekmede Aç ↗

↗Yeni Sekme

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

Wilson JD, Fasten DW, Textbook of Williams Endocrinology.Fifth Edition, W.B.Saunders Company, Philadelphia. 1992, 32:1569
Greenspen FS, Godre RG. Basic Clinical Endocrinology. Sixth Edition. Me Graw Hill.New York. 1992;17; 617
Sweet RD. Dermatosis specifically associated with a tumor of pancreatic alpha cells. Br J Dermatol,1974;90:301-8
Wilkinson AS. Necrolytic migratory erytema with carcinoma of the pancreas. Trans St John's Hose Dermatol So 1973;59:244-50
Bloom SR, Polak JM. Glucagonoma Syndrome, Am J Med. 1987; 82:25-36
Binnick AN, Spencer SK, Dennison WL, et al: Glucagonoma Syndrome, Report of two cases and literature review. Arch Dermatol 1997;113:749-54
Stacpoole PW. The glucagonoma syndrome clinical features, diagnosis and treatment. Endocrinol Rew, 1997; 2:347-61. 8: Mallinson CN, Bloom SR, Warin AP. A glucagonoma syndrome. Lancet 1974; 2:1-5. 9: Wood SM, Polak JM, Bloom SR.GIucagonoma syndrome In: Lefebure PJ ed. Handbook of Experimental Pharmacology. Vol 66 part:2. Glucagon. Stuttgard. Springer-Verlag, 1983; 411-30
Higgins GA, Recont L, Fiscman AB. The glucagonoma syndrome: surgically curable diabetes. Am J Surg 1979; 137:142-148 11. Almdal TP, Heindorff H, Bordram L et al: Increased amino acid clearence and urea synthesis in a patient with glucagonoma. Gut 1990; 31:946-48
Chastain MA. The glucagonoma syndrome: a review of its features and discussion perspectives. Am J Med Sci 2001; 21(5);396-20. 13: Hicks T, Tumberg LA. lanfluence of glucagon on the human jejunum. Gastroenterology 1974; 67:1114-18
Santargelo WC, Unger RH, Orci L et al. Somatostatin analoque- induced remission of necrolytic migratory eryhemo without changes in plasma glucagon concentrantations. Pancreas 1986; 1:464-69
Nishiguchi S, Shiami S, İshuzu H. A case of glucagonoma with high uptake on F-18 fluorodeoxyglucose PET. Ann Nucl Med 2001; 15 (3): 259-62
Brentjens R, Soltz L. Islet cell tumors of the pancreas the medical oncologist's perspectives. Surg Clin North Am 2001;81 (3); 527-42.